이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

A Phase II Study Assessing Tumor Blood Flow as Measured by Dynamic Contrast Enhanced MRI in Patients With Metastatic Colorectal Cancer Receiving FOLFOX Alone Versus Patients Randomized to Receive FOLFOX Plus Bevacizumab at 5mg/kg or 10mg/kg.

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving bevacizumab together with combination chemotherapy may kill more tumor cells. Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This randomized phase II trial is studying how well MRI works in predicting response to combination chemotherapy given together with bevacizumab in treating patients with advanced or metastatic colorectal cancer.

연구 개요

상세 설명

OBJECTIVES:

Primary

  • To determine the alteration of tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with advanced or metastatic colorectal cancer after 2 courses of combination chemotherapy comprising oxaliplatin, fluorouracil, and leucovorin (FOLFOX) and bevacizumab at 5 mg/kg vs 10 mg/kg or FOLFOX alone.

Secondary

  • To correlate tumor blood flow, as assessed by DCE-MRI, with time to progression in patients receiving bevacizumab at 5mg/kg vs 10mg/kg.
  • To correlate vascular proliferation, as measured by DCE-MRI, with markers of endothelial cell proliferation (i.e., CD31, 34, 105; integrin αvß3; phospho-ERK; Ki67; PCNA; and smooth muscle actin).
  • To obtain pilot data on whether assays that measure vascular endothelial cell mitogenic stimulation and mitogenic activity may predict response to therapy, time to progression, and overall survival of patients receiving bevacizumab at 5mg/kg vs 10mg/kg.
  • To investigate the association of various markers of apoptosis in tumor cells (e.g., MIF, CREB, or HIF-1-alpha expression/polymorphism and others) and tumor vascularity, as assessed by DCE-MRI.
  • To correlate markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival.
  • To determine serum levels of VEGF prior to the initiation of chemotherapy and then prior to courses 2 and 3 of chemotherapy as potential markers of antiangiogenic activity.

OUTLINE: Patients who are eligible to receive bevacizumab are randomized to 1 of 2 treatment arms. Patients who are ineligible to receive bevacizumab receive FOLFOX alone.

  • Arm I: Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours (FOLFOX) beginning on day 1. Patients also receive bevacizumab at 5 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
  • FOLFOX alone (control): Patients receive FOLFOX as in arm I. All patients undergo dynamic contrast-enhanced MRI at baseline and between courses 2 and 3 (between days 17 and 29) to assess tumor blood flow.

Tumor tissue specimens are obtained from prior colonoscopic biopsy or surgical resection in patients receiving bevacizumab. Tissue specimens are examined by immunohistochemistry to evaluate tumor markers of angiogenesis and apoptosis (e.g., CD31, 34, 105, phospho-ERK, PCNA, Ki67, SMA, and integrin αvß3). Blood specimens are obtained at baseline and prior to courses 2 and 3 (days 15 and 29) to evaluate plasma levels of VEGF.

After completion of study therapy, patients are followed every 2 months for 1 year and then every 3 months thereafter.

연구 유형

중재적

등록 (실제)

5

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104-4283
        • Abramson Cancer Center of the University of Pennsylvania

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

DISEASE CHARACTERISTICS:

  • Histologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum
  • Patients receiving bevacizumab must have tumor tissue available for immunohistochemical analysis

    • Formalin-fixed, paraffin-embedded tissue from previous biopsy or surgical resection is sufficient
  • Measurable disease, defined by RECIST as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm by conventional techniques (i.e., CT or MRI)

    • CEA elevation alone is insufficient for study entry
  • No known brain metastases

PATIENT CHARACTERISTICS:

Criteria for all patients

  • ECOG performance status 0-1
  • Life expectancy > 3 months
  • Granulocytes ≥ 1,500/mL
  • Platelet Count ≥ 100,000/mL
  • Creatinine ≤ 1.5 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN
  • AST ≤ 5 times ULN
  • Urine protein:creatinine ratio ≤ 1.0 at screening
  • Patients with other prior malignancies are eligible, provided they have been treated with curative intent and have no evidence of recurrence
  • Not pregnant or nursing
  • Negative pregnancy test
  • No contraindications to MRI, including any of the following:

    • Hypersensitivity to gadolinium
    • Metallic device, including pacemaker, non-MRI compatible aneurysm clip, other non-MRI-compatible mechanical and/or electrical device, or metallic fragments
    • Severe claustrophobia

Additional criteria for patients receiving bevacizumab:

  • No significant traumatic injury within the past 28 days
  • No serious nonhealing wounds, ulcers, or bone fractures
  • No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
  • No myocardial infarction, unstable angina, or cerebrovascular accident within the past 6 months
  • No clinically significant peripheral vascular disease
  • No New York Heart Association class II-IV congestive heart failure
  • Patients with pre-existing hypertension should be on a stable antihypertensive regimen with blood pressure ≤ 150/100 mm Hg at study entry

PRIOR CONCURRENT THERAPY:

Criteria for all patients

  • Prior adjuvant treatment including oxaliplatin allowed
  • No prior bevacizumab
  • At least 14 days since prior radiotherapy and recovered
  • More than 6 months since prior chemotherapy
  • No other concurrent investigational agents

Additional criteria for patients receiving bevacizumab:

  • At least 28 days since prior major surgical procedure or open biopsy
  • At least 7 days since prior minor surgical procedure (e.g., fine-needle aspirations or core biopsies)
  • No anticipation of need for a major surgical procedure during study treatment
  • Concurrent oral or parenteral anticoagulation therapy allowed provided dose is stable

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 특수 증상
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm I
Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours (FOLFOX) beginning on day 1. Patients also receive bevacizumab at 5 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
주어진 IV
주어진 IV
주어진 IV
주어진 IV
실험적: Arm II
Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
주어진 IV
주어진 IV
주어진 IV
주어진 IV
활성 비교기: FOLFOX alone (control)
Patients receive FOLFOX as in arm I.
주어진 IV
주어진 IV
주어진 IV

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Analysis of tumor blood flow, assessed by DCE-MRI as percentage change in Ktrans, after 2 courses of FOLFOX and bevacizumab or FOLFOX alone compared to baseline value
기간: 2 cycles for all subjects
2 cycles for all subjects

2차 결과 측정

결과 측정
기간
Analysis of tumor markers of angiogenesis and apoptosis, and the effect of treatment
기간: 2 cycles for all subjects
2 cycles for all subjects
Correlation of tumor blood flow with time to progression
기간: 2 cycles
2 cycles
Correlation of markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival
기간: 2 cycles for all subjects
2 cycles for all subjects

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2006년 2월 1일

기본 완료 (실제)

2009년 7월 1일

연구 완료 (실제)

2009년 10월 1일

연구 등록 날짜

최초 제출

2008년 1월 19일

QC 기준을 충족하는 최초 제출

2008년 1월 19일

처음 게시됨 (추정)

2008년 1월 28일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2020년 4월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2020년 4월 24일

마지막으로 확인됨

2020년 4월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다